A Phase II Trial of Prolonged Oral Etoposide (VP-16) as Second-Line Therapy for Advanced and Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

Author: Rose P.G.   Blessing J.A.   Lewandowski G.S.   Creasman W.T.   Webster K.D.  

Publisher: Academic Press

ISSN: 0090-8258

Source: Gynecologic Oncology, Vol.63, Iss.1, 1996-10, pp. : 101-104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content